Hormone therapies have played a major role in improving survival for patients with ER+ breast cancer [1]. By blocking or reducing estrogen’s impact, these treatments slow the cancer’s growth ...

Breastfeeding is widely recognized for its role in infant nutrition ... suppresses estrogen, a hormone linked to Hormonal Receptor positive breast cancer (HR-positive). 1 Additionally, breast ...

ER+/PR+ breast cancer is a subtype of ER positive breast cancer where the tumor cells express both estrogen receptors (ER) and progesterone receptors (PR) on the surface. As the most common type ...

While it’s true that soy isoflavones play a bigger role in estrogen-receptor positive breast cancers, early research links it to a lower risk of other types of breast cancer. That finding comes ...

Turns out it was the estrogen. I was gaining all this weight.” According to the Cleveland Clinic, most cribriform carcinoma breast ... part of her cancer journey. Getty Images “I have a ...

Elacestrant (Orserdu) is an oral drug that binds to estrogen receptors used to treat postmenopausal women or men with certain types of advanced breast cancer with an ESR1 mutation. Abemaciclib ...

Estrogen-dependent cancers are cancers that grow in response to the hormone estrogen. These include certain types of breast cancer, uterine cancer, and ovarian cancer. In these cancers, estrogen ...

Despite improved treatments and a significant rise in the number of survivors, breast cancer still stands ... compounds can mimic or oppose estrogen effects, offering new angles in understanding ...

Long-term estrogen imbalance can lead to more serious health problems, such as fibroids, endometriosis, or an increased risk of developing certain types of cancer, including breast cancer.

According to the National Cancer Institute, roughly 15% of breast cancer cases are hormone-receptor negative, in which breast cancer cells do not contain hormone (estrogen or progesterone) receptors.